Los valores persistentemente positivos de anticuerpos antifosfolipídicos están relacionados con la aparición de trombosis durante el seguimiento de pacientes con síndrome antifosfolipídico / Persistenly positive antiphospholipid antibodies are related with the appearance of thrombosis during follow-up with antiphospholipid syndrome

RESUMEN

Objetivo: determinar si la presencia de valores persistentemente positivos de anticuerpos antifosfolipídicos (AAF) está relacionada con trombosis recurrente en el seguimiento de pacientes con síndrome antifosfolipídico (SAF). Métodos: se analizaron 141 pacientes con SAF (criterios de Sapporo). Los valores de anticoagulante lúpico (AL) y anticuerpos anticardiolipina (AAC) fueron definidos como persistentemente positivos cuando más del 75% de las determinaciones fueron positivas durante el seguimiento (los AAF fueron medidos en cinco o más ocasiones). La trombosis en el seguimiento fue definida como una trombosis recurrente en pacientes con episodios trombóticos previos o nuevos episodios en aquellos pacientes con pérdidas fetales previas. Resultados: ochenta y nueve pacientes presentaban SAF primario, 34 asociado a lupus eritema-toso sistémico (LES), 14 con síndrome similar al lupus, 3 con síndrome de Sjogren y 1 con enfermedad de Beh

ABSTRACT

Objective: to determine if the presence of persistently positive valúes of antiphospholipid (aPL) antibodies is related with recurrent thrombosis in the follow-up of patíent with antiphospholipid syndrome (APS). Patients and Methods: 141 patients with APS (Sapporo's criteria) were analyzed. Lupus antico-agulant (LAC) valúes and anticardiolipin antibodies (aCL) were defined as persistently positive when more than 75% of determinations were positive during the follow-up (aPL were measured on 5 or more occasions). Thrombosis in the follow-up was defined as a recurrent thrombosis in patient with previous thrombotic events or new events in those patients with previous fetal losses. Results: 89 patients suffered from primary APS, 34 associated to systemic lupus erythematosus (SLE), 14 to SLE-like, 3 to Sjogren's syndrome, and 1 to Behcet's disease. 56% liad a history of thrombosis, 29% of fetal losses, and 15% both thrombosis and fetal losses. Median time of follow-up and between the diagnosis and the last aPL determination was 68 months and 65 months (9-180), respectively. Median of determinations by patient was 8 (5-27). 31 patients suffered from thrombosis in the follow-up, 28 of them in form of recurrent thrombosis. 58 (41%) patients liad persistently positive aPL during follow-up, thus: 23 (39,65%) aCL IgG y LAC, 12 (20,7%) LAC, 8 (13,8%) aCL IgG, 5 (8,6%) aCL IgM, aCL IgG y LAC, 4 (6,9%) aCL IgM, 3 (5,1%) aCL IgG y aCL IgM y 3 (5,1%) aCL IgM y LAC, respectively. Risk for recurrent thrombosis during follow-up was increased in persistently positive aPL patients (OR 3,53; 95% CI 1,53-8,16; p=0,003) compared with transiently positive aPL patients. This higher risk was attributable to persistently positive LA (OR 3,87; 95% CI 1,68-8,91; p=0,002) and persistently positive aCL IgG (OR 2,91; 95% CI 1,25-6,75; p=0,02). The profile of persistently positive aPL related with the appearance of thrombosis during follow-up was the combination of IgG aCL & LA (OR 3,51; 95% CI 1,36-9,09; p=0,01). Conclusions: the risk of thrombosis during follow-up is increased in patients with persistently positive aPL, specially in those with the combination of IgG aCL & LA.

ABSTRACT

Objective: to determine if the presence of persistently positive valúes of antiphospholipid (aPL) antibodies is related with recurrent thrombosis in the follow-up of patíent with antiphospholipid syndrome (APS). Patients and Methods: 141 patients with APS (Sapporo's criteria) were analyzed. Lupus antico-agulant (LAC) valúes and anticardiolipin antibodies (aCL) were defined as persistently positive when more than 75% of determinations were positive during the follow-up (aPL were measured on 5 or more occasions). Thrombosis in the follow-up was defined as a recurrent thrombosis in patient with previous thrombotic events or new events in those patients with previous fetal losses. Results: 89 patients suffered from primary APS, 34 associated to systemic lupus erythematosus (SLE), 14 to SLE-like, 3 to Sjogren's syndrome, and 1 to Behcet's disease. 56% liad a history of thrombosis, 29% of fetal losses, and 15% both thrombosis and fetal losses. Median time of follow-up and between the diagnosis and the last aPL determination was 68 months and 65 months (9-180), respectively. Median of determinations by patient was 8 (5-27). 31 patients suffered from thrombosis in the follow-up, 28 of them in form of recurrent thrombosis. 58 (41%) patients liad persistently positive aPL during follow-up, thus: 23 (39,65%) aCL IgG y LAC, 12 (20,7%) LAC, 8 (13,8%) aCL IgG, 5 (8,6%) aCL IgM, aCL IgG y LAC, 4 (6,9%) aCL IgM, 3 (5,1%) aCL IgG y aCL IgM y 3 (5,1%) aCL IgM y LAC, respectively. Risk for recurrent thrombosis during follow-up was increased in persistently positive aPL patients (OR 3,53; 95% CI 1,53-8,16; p=0,003) compared with transiently positive aPL patients. This higher risk was attributable to persistently positive LA (OR 3,87; 95% CI 1,68-8,91; p=0,002) and persistently positive aCL IgG (OR 2,91; 95% CI 1,25-6,75; p=0,02). The profile of persistently positive aPL related with the appearance of thrombosis during follow-up was the combination of IgG aCL & LA (OR 3,51; 95% CI 1,36-9,09; p=0,01). Conclusions: the risk of thrombosis during follow-up is increased in patients with persistently positive aPL, specially in those with the combination of IgG aCL & LA.